Currently Viewing
A New Drug for Mantle Cell Lymphoma On Its Way to Approval
August 04, 2017 – Jason Harris
FDA Approves Vyxeos for Two Leukemia Types
August 03, 2017 – Silas Inman
Imbruvica Approved to Treat Chronic GVHD
August 02, 2017 – Jason M. Broderick
Dumb Things People Say to People With Cancer
August 02, 2017 – Staff
Idhifa Approved by the FDA to Treat Relapsed AML
August 01, 2017 – Silas Inman
Opdivo Granted FDA Approval for Some Colorectal Cancers
August 01, 2017 – Jason M. Broderick
Parent Age May Affect Child's Cancer Risk, Study Finds
July 31, 2017 – Brielle Urciuoli
Antiperspirant Use OK for Women Getting Breast Radiation
July 28, 2017 – Don Henry
Patients' Gray Hair Turns Dark After Immunotherapy for Lung Cancer
July 27, 2017 – Mindy Waizer

A New Drug for Mantle Cell Lymphoma On Its Way to Approval

Acalabrutinib was granted a priority review to a new drug application (NDA) to be used to treat patients with mantle cell lymphoma (MCL) who have had previous treatment, according to AstraZeneca, the manufacturer of the drug.
 
BY Jason Harris
PUBLISHED August 04, 2017
Acalabrutinib was granted a priority review to a new drug application (NDA) to be used to treat patients with mantle cell lymphoma (MCL) who have had previous treatment, according to AstraZeneca, the manufacturer of the drug.

The announcement comes just one day after AstraZeneca reported that acalabrutinib had received an FDA breakthrough therapy designation in this setting. The NDA is supported, in part, with phase 2 results from the ACE-LY-004 trial evaluating the safety and efficacy of acalabrutinib in patients with relapsed/refractory MCL. The company has not made any data from that trial available, but a spokesperson wrote in an email that the data is slated to be presented at a medical meeting later this year.

Under the Prescription Drug User Fee Act, the FDA is scheduled to issue its final approval decision for acalabrutinib in this setting by early next year.

Acerta Pharma, AstraZeneca’s hematology research and development center of excellence, developed acalabrutinib to treat multiple B-cell cancers, including multiple myeloma and chronic lymphocytic leukemia (CLL), alone or in combination. The company is currently recruiting patients with previously untreated MCL for the phase 3 ACE-LY-308 clinical trial evaluating acalabrutinib in combination with bendamustine and Rituxan (rituximab) (BR) versus placebo plus BR.

“We believe acalabrutinib has the potential to be a very important treatment option for patients with this life-threatening blood cancer,” Flavia Borellini, Ph.D., Acerta Pharma CEO, said in a press release. “The FDA’s NDA acceptance exemplifies our progress in the acalabrutinib development program and continues our momentum as we seek to transform care for people with hematologic malignancies.”

MCL is an aggressive B-cell non-Hodgkin lymphoma with a poor prognosis. The disease accounts for up to 6 percent of new non-Hodgkin lymphoma cases in Western countries each year, with an annual incidence of 0.5 per 100,000 persons and an estimated prevalence of 3.5 per 100,000.

Patients with advanced MCL have seen an increase in treatment options in recent years. In 2013, the FDA approved Imbruvica (ibrutinib) for patients with MCL who have received at least one prior therapy, and Revlimid (lenalidomide) for patients who have relapsed or whose disease has progressed after two prior therapies, including at least one prior treatment with Velcade (bortezomib).

Velcade was approved for patients with previously treated MCL in 2006 and for previously untreated patients in 2014.

Available data for acalabrutinib have demonstrated promising activity in patients with CLL and small lymphocytic leukemia (SLL). Results from the phase 1/2 ACE-CL-001 trial presented at the 2016 ASH Annual Meeting showed that the overall response rate (ORR) was 79 percent with acalabrutinib in patients with Imbruvica-intolerant CLL/SLL.

Of 29 patients evaluable for response, best response was a complete response (CR) in 1 patient (3.4 percent), a partial response (PR) in 15 (51.7 percent), PR with lymphocytosis (PRL) in 7 (24.1 percent), and stable disease (SD) in 6 (20.7 percent). The ORR when including only CR plus PR was 55.2 percent, and was 79.3 percent when including PRL in the ORR definition. All evaluable patients achieved at least SD. The median time to PRL or better was 1.9 months.

In a separate abstract presented at the 2016 ASH Annual Meeting, acalabrutinib demonstrated an ORR of 38.1 percent in a cohort of patients with Richter transformation from the same ACE-CL-001 trial.
Be the first to discuss this article on CURE's forum. >>
Talk about this article with other patients, caregivers, and advocates in the Lymphoma Cancer CURE discussion group.

Related Articles

1
×

Sign In

Not a member? Sign up now!
×

Sign Up

Are you a member? Please Log In